Point72 Discloses 6.7% Stake in Pliant Therapeutics (4.09M Shares)
Point72 Asset Management and affiliates report beneficial ownership of 4,085,017 shares of Pliant Therapeutics, Inc. (PLRX), representing 6.7% of the outstanding common stock as of the close of business on September 3, 2025.
Rhea-AI Filing Summary
Point72 Asset Management and affiliates report beneficial ownership of 4,085,017 shares of Pliant Therapeutics, Inc. (PLRX), representing 6.7% of the outstanding common stock as of the close of business on September 3, 2025. The filing is a Schedule 13G showing that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen share voting and dispositive power over these shares and that the shares are held by an investment fund managed by Point72 Asset Management (Point72 Associates).
The statement clarifies that none of the reporting persons own shares directly and that Point72 Associates has the right to receive dividends or sale proceeds for more than 5% of the class. A Joint Filing Agreement (Exhibit 99.1) is referenced.
Positive
- Disclosure of material ownership: Point72 reports a clear beneficial ownership stake of 4,085,017 shares representing 6.7% of PLRX.
- Joint Filing Agreement referenced: The filing cites an Exhibit 99.1 joint filing agreement, clarifying coordination among reporting persons.
- Certification of passive intent: The filing includes a certification that the shares were not acquired to change or influence control of the issuer.
Negative
- None.
Insights
TL;DR: Point72 holds a meaningful 6.7% stake in PLRX via managed funds, signaling notable institutional ownership without intent to influence control.
The Schedule 13G discloses a 6.7% beneficial ownership position by Point72-related reporting persons, consistent with passive/investment-adviser reporting under Rule 13d-1. Reported shared voting and dispositive power of 4,085,017 shares indicates centralized portfolio management via Point72 Associates. The filing date and specified ownership as of September 3, 2025, provide a clear snapshot of institutional exposure but include no transactions, timing of purchases, or economic terms.
TL;DR: A formal joint 13G filing documents control relationships and confirms that the position is held for investment, not for changing issuer control.
The document includes a Joint Filing Agreement among Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen and contains the certification that the securities were not acquired to change or influence control of the issuer. The filing identifies shared voting/dispositive power and notes that Point72 Associates can direct dividends or sale proceeds exceeding 5% of the class—an important disclosure for governance transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who filed the Schedule 13G for PLRX on behalf of Point72?
Does the filing state whether Point72 intends to influence control of Pliant Therapeutics?
AI-generated analysis. How Rhea-AI works. Not financial advice.